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1. Introduction  
Chemotherapy-induced alopecia (CIA) is a frequent toxicity and arguably the most feared 
side effect of cancer chemotherapy (Carelle et al., 2002). The incidence of CIA is 
approximately 65% of all patients (Wang et al., 2006). CIA could be easily noticeable by self 
and others in a relative short time, thus it is linked with having cancer and chemotherapy. 
CIA compromises patient quality of life, especially for female and children, leading to poor 
therapeutic outcome. Despite significant progresses and substantial efforts in CIA research 
and development, no reliable and effective preventive treatment has become available. This 
limitation has been attributed to the lack of basic understanding of CIA pathogenesis and 
appropriate experimental models. This chapter will provide an overview of the basic and 
clinical aspects of CIA including hair follicle biology, characteristics of CIA along with the 
state-of-the-art experimental models and treatment strategies. Experimental approaches for 
pharmacologic inhibition of CIA including drug-specific antibodies, hair growth cycle 
modifiers, cytokines, growth factors, antioxidants, cell cycle modifiers, and apoptosis 
inhibitors will be discussed. Current understanding in the molecular mechanisms of CIA 
and the role of specific genes, e.g. p53 and Fas, in the process will also be discussed. The 
chapter will conclude with the perspective on the prevention and management of CIA.  
2. Hair follicle biology 
Chemotherapy causes structural damage of human scalp hairs. The effects may vary from 
altered hair appearance, decreased rate of hair growth, partial or complete hair loss 
(alopecia). To discuss the advances in the pathogenesis of CIA, an overview of hair follicle 
biology is first covered.   
2.1 Hair follicle structure 
Hair follicle structure changes during the various stages of hair growth cycle (see Section 2.2 
for review). In the anagen phase, hair structure is composed of two distinct components, 
hair follicle and hair shaft (Fig. 1a). The hair follicle is embedded in the connective tissue 
and subcutaneous fat. Contained within the hair follicle bulb is the pluripotent keratinocytes 
of hair matrix. Matrix cells in the lower part of hair bulb constantly divide at a high mitotic 
rate, whereas the matrix cells in the upper part of hair bulb have a low mitotic rate and 
could differentiate to form the inner root sheath (IRS) and hair shaft (HS), which are the 
www.intechopen.com
 
Topics in Cancer Survivorship 
 
54
middle and innermost layer of hair follicle, respectively. Outer root sheath (ORS), is the 
outermost layer of hair follicle that separates the whole organ from dermis and is believed to 
contain epithelial stem cells at its bulge region (Hardy, 1992; Krause and Foitzik, 2006; 
Alonso and Fuchs, 2006). Pigmentation of hair shaft depends on melanocytes, which reside 
in the hair matrix of hair follicle. Melanocytes transfer the melanin granule to keratinocytes 
of the growing hair shaft (Ohnemus et al., 2006). Besides the epithelial cells, hair follicle also 
contains the mass of mesenchymal dermal papilla (DP) cells at its base (Fig. 1b). The DP cells 
are connected to capillaries to derive nutrients from the blood and also function as a 
regulator of hair cycle (Sakita et al., 1995). Moreover, substantial evidence supports the 
correlation between DP cell number and the size of hair follicle and shaft (Elliot et al., 1993; 
Ishino et al., 1997). 
 
 
Fig. 1. Diagrammatic representation of hair follicle structure in its mature anagen phase. (a) 
A full-length longitudinal view of hair follicle. (b) Hair follicle bulb. Abbreviations: APM, 
arector pili muscle; B, bulge; CTS, connective tissue sheath; CTX, cortex of hair shaft; CU, 
cuticle of hair shaft; DP, dermal papilla; E, epidermis; HM, hair matrix; HS, hair shaft; IRS, 
inner root sheath; M, melanocytes; ORS, outer root sheath; S, sebaceous gland. 
2.2 Hair growth cycle 
Each hair follicle undergoes rhythmic changes through the three phases of hair cycle, which 
are anagen, catagen and telogen (Fig. 2). Anagen is an active growth phase of hair follicle. 
During anagen, daughter cells of pluripotent keratinocytes move upwards and adapt into 
one of the six epithelial lineages, namely Henley, Huxley and cuticle of the IRS and cuticle, 
cortex and medulla of the HS. As the HS cells become fully differentiated, they extrude their 
organelles and are tightly packed to form cysteine-rich hair keratins. The IRS and HS 
interlock via their cuticle structures, however, the IRS degenerates in the upper follicle, 
thereby releasing the HS that continues to move towards the skin surface. Subsequently, the 
hair follicle enters the catagen or regression phase. During catagen, there are extensive 
apoptosis of epithelial cells in the hair follicle bulb and ORS, leading to the formation of 
epithelial strands. The HS hence stops differentiation and forms the club hair, which moves 
up until it reaches the bulge region. Dermal papilla cells are condensed and move upwards 
to the bulge region. After that, the hair enters the telogen or resting phase. In this phase, the 
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HS exhibits no significant proliferation, apoptosis or differentiation. The transition from 
telogen to anagen occurs when the bulge stem cells are activated (Cotsaleris and Millar, 
2001; Krause and Foitzik, 2006; Alonso and Fuchs, 2006; Ohnemus et al., 2006). 
 
 
Fig. 2. Hair growth cycle. A new hair shaft is produced during anagen, and the old hair is 
released from the follicle as the new shaft develops. Anagen VI (mature anagen) is the stage 
where new HS reaches the skin surface and continues to grow through the rest of anagen. 
During catagen, the lower two thirds of the epithelial follicle are regressed. The hair 
develops a club structure, which retains the hair in the follicle. Then, the follicle enters a 
telogen phase until a new growth cycle is activated. Abbreviations: B, bulge; DP, dermal 
papilla; HS, hair shaft.  
3. Chemotherapy-induced alopecia 
CIA or hair loss caused by chemotherapy is the most common cutaneous side effect of 
chemotherapy. CIA ranks among patients as a severe side effect that affects their quality of 
life.   
3.1 Impact on cancer therapy 
CIA has an enormous psychological and social impact on patients, which can be summarized 
as: (i) symbol of cancer for self (constant reminder of their treatment) and others (outwardly 
visible); (ii) personal confrontation of being ill or mortality; (iii) vulnerability; (iv) 
powerlessness; (v) shame; (vi) loss of privacy; (vii) punishment, and (viii) change in self and 
other perception (Freedman, 1994; Pozo-Kaderman et al., 1999). Female and children have 
more difficulties coping with the CIA. Indeed, up to 8% of women are reported to reject 
chemotherapy for fear of CIA (Mundstedt et al., 1997; McGarvey et al., 2001). CIA also results 
in reduced social activities since hair partly plays a role in social and sexual communications 
(Batchelor, 2001). Additionally, these negative impacts of CIA may contribute to poor 
therapeutic outcome, as stress and depression lowers the body’s immune function and is 
highly associated with cancer progression (Spiegel and Giese-Davis, 2003; O’Leary, 1990).  
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B B B
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3.2 Pathophysiology 
The basic principle of chemotherapy is to impair the mitotic and metabolic process of cancer 
cells. Unfortunately, certain normal cells and tissues with rapid metabolic and mitotic rates 
such as the hair follicles are also affected by the chemotherapy. Up to 90% of hair follicles 
undergo anagen, an active growth phase, at a given time. The rapid hair growth as well as 
the high blood flow rate around the hair bulb leading to the accumulation of drugs is a key 
predisposing factor for rapid and extensive alopecia (Batchelor, 2001). In humans, CIA 
usually begins approximately 2 to 4 weeks and is complete at 1 to 2 months after the 
initiation of chemotherapy (Batchelor, 2001). Hair might be easily depilated as early as 1 to 2 
weeks after the treatment due to the weakening and breakage of hair shaft. The hair would 
fall out upon combing and in the bedding area. The degree of CIA depends on the type of 
chemotherapy, dosage regimen and route of administration. Almost all chemotherapies 
cause alopecia but with varying degrees of severity and frequency (Apisanthanarax and 
Duvic, 2003) as summarized in Table 1.  
 
More common or severe Less common or severe 
Bleomycin 
Cytarabine 
Dacarbazine 
Docetaxel 
Etoposide 
Idarubicin 
Interferon-α 
Mechlorethamine 
Paclitaxel 
Topotecan 
Vincristine 
Cyclophosphamide 
Cisplatin 
Dactinomycin 
Doxorubicin 
Fluorouracil 
Ifosfamide 
Irinotecan 
Nitroureas 
Thiotepa 
Vinblastine 
Vindesine 
Amscarine 
Carmusine  
Carboplatin 
Gemcitabine 
Interleukin-2 
Mercaptopurine 
Mitomycin 
Procarbazine 
Vinorelbine 
Busulfan 
Chlorambucil 
Epirubicin 
Hydroxyurea 
Melphalan 
Methotrexate 
Mitoxantrone 
Teniposide 
Table 1. Chemotherapeutic agents associated with alopecia.  
A high-dose intravenous chemotherapy is commonly associated with more rapid and 
extensive alopecia. By contrast, oral therapy at lower doses on a weekly schedule tends to 
cause less alopecia even though the total dose may be large (Wilkes, 1996). Combination 
therapy consisting of two or more chemotherapeutic agents normally causes a higher 
incidence and more severe CIA compared to single agent therapy. Long-term chemotherapy 
may also result in the loss of pubic, axillary and facial hair. 
CIA is usually reversible with the hair regrowth generally occurring 3 to 6 months after the 
end of treatment. However, in most cases the new hair is grey or differs in color, 
representing the distortion of pigmentation process. Moreover, the new hair typically 
exhibits some changes in hair structure and texture, e.g. coarser, slow growth, and reduced 
density (Wang et al., 2006; Trueb, 2009). Permanent alopecia has been reported but rarely 
occurs (Betcheler, 2001).  
4. Experimental models 
4.1 Animal models 
Due to the ethical problems in obtaining scalp biopsies from chemotherapy patients, little is 
known about the mechanisms of CIA in humans. In the last decade, important information 
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about the CIA comes mostly from animal models. The commonly used animal models are 
neonatal rats and adult mice. However, there are some differences in human and rat/mouse 
hair growth pattern. In humans, the hair growth cycle occurs in a mosaic or asynchronous 
pattern, where the growth cycle of individual hair follicles is independent of neighbouring 
hair follicles. In contrast, rodent hair growth occurs in a wave pattern, beginning from the 
head and moving towards the tail. A group of hair follicles at a specific area are usually in 
the same stage of hair cycle. In general, only 10% of hair follicles in adult mice or rats are in 
the anagen phase as compared to 90% in adult humans. Some animals including guinea pigs 
and Angora rabbits exhibit a mosaic hair growth pattern but are not commonly used due to 
their insensitivity to CIA.  
4.1.1 Neonatal rat model 
The early model for CIA was established in newborn rats (Hussein et al., 1990; Hussein, 
1993). Seven to eight-day old Sprague Dawley rats exhibit spontaneous anagen hair growth 
for about a week. In this model, administration of chemotherapeutic agents such as cytosine 
arabinoside, doxorubicin, cyclophosphamide, and etoposide induces alopecia one week 
after the treatment with the severity of CIA depending on the agents (Hussein et al., 1990; 
Hessein, 1991; Jimenez and Yunis, 1992).  
The major advantage of neonatal rat model is the rapid and easily noticeable CIA due to 
progressive hair loss from the head and throughout the body in about 2 days. Several 
drawbacks and limitations of this animal model have been reported. For examples, the 
level of growth factors and cytokines and the hair follicle structure in neonatal rats differ 
substantially from those in mature animals, thus altering the response of hair follicles to 
treatment agents. Also, the lack of hair pigmentation in Sprague Dawley rats, which have 
a white fur, limits the study of drug effects on melanocytes. Indeed, some observations in 
newborn rats appear irrelevant to humans. For instance, the protective effect of topical 
application of 1,25-dihydroxyvitamin D3 on alopecia induced by cyclophosphamide was 
observed in neonatal rats but not in humans (Jimenez and Yunis, 1992; Hidalgo et al., 
1999). 
4.1.2 Adult mouse model 
The adult black C57BL/6 mouse model for CIA was first developed in 1994 (Paus et al., 
1994). In this mouse strain, the skin melanocytes are confined to hair follicles and the stage 
of hair growth is indicated by the skin color, i.e., pink during the telogen phase and black 
during the anagen phase. To mimic human hair scalp, depilation is performed to induce the 
mouse hair follicles at telogen phase to enter anagen phase, which is normally achieved in 
about 9 days. At around 16 days after the depilation, morphological signs of catagen are 
detectable. At day 20 after the depilation, all hair follicles are in the telogen phase. The CIA 
model was used to study the effect of cyclophosphamide (120-150 mg/kg, ip) on day 9 after 
the depilation (anagen phase). Cyclophosphamide was found to induce premature catagen 
development, dystrophic follicles, and complete alopecia in 6 days. In the past decade, 
progress in the understanding of hair follicle damage and pathogenesis of CIA has been 
obtained largely by using this model. On a cellular level, cyclophosphamide induces 
massive apoptosis of keratinocytes and melanocytes, although the precise mechanism of 
induction is largely unknown (Hendrix et al., 2005).  
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4.2 Culture models 
4.2.1 Organ culture model 
Although animal models have provided valuable information regarding the pathogenesis of 
CIA, the animal physiological and pathological conditions do not necessarily mimic human 
conditions. The first human organ-culture hair follicle model for CIA was developed in 2007 
(Bodo et al., 2007). In this model, mature anagen (anagen VI) human hair follicles are micro-
dissected intact from the occipital scalp of healthy adults. The isolated hair follicles are 
maintained in William’s E medium containing L-glutamine, hydrocortisone, and insulin. 4-
Hydroperoxycyclophosphamide (4-HC), a key cyclophosphamide metabolite, was used to 
verify key in vivo characteristics of CIA since clinical and animal data of cyclophosphamide-
induced CIA are well established. 4-HC was shown to induce melanin clumping and 
incontinence, reduce keratinocyte proliferation, induce keratinocyte and dermal papilla cell 
apoptosis, and induce premature catagen, resembling in vivo hair follicle dystrophy. 
Comparison of the test results in adult mouse model and organ culture model in response to 
cyclophosphamide is shown in Table 2. The human organ-culture hair follicle system could 
be used to study the pathogenesis and potential treatment of CIA, i.e., to identify key 
molecular targets and inhibitors of CIA.   
 
Key clinical parameters Adult mouse model Organ culture model 
Inhibition of hair shaft elongation 
Increased apoptosis of matrix 
keratinocytes 
Decreased proliferation of matrix 
keratinocytes 
Catagen induction 
Disrupted melanogenesis and 
melanin transfer 
Not directly 
Yes 
 
Not assessed 
 
Yes 
Yes 
Yes 
Yes 
 
Yes 
 
Yes 
Yes 
Table 2. Comparison of adult mouse model and organ culture model. 
4.2.2 Cell culture model 
Keratinocytes, dermal papilla cells, and melanocytes constitute the major cell types in the 
hair follicle. In CIA, massive apoptosis of keratinocytes occurs; thereby cultured 
keratinocytes are commonly used as a predictive model for chemotherapy-induced hair 
follicle damage. Primary and immortalized normal human keratinocytes (HaCaT) have been 
used to test the effects of chemotherapeutic agents and protectants (Matsumoto et al., 1995; 
Braun et al., 2006; Janssen et al., 2008). However, since different hair follicle cells interact and 
affect each other cell growth and cycling (Rogers and Hynd, 2001), the effects of 
chemotherapeutic agents on other cell types, e.g., dermal papilla cells and melanocytes, 
should also be evaluated, i.e., through the use of a co-culture system. Furthermore, current 
cell culture models lack biological measures of hair growth and cycling; however, they offer 
the advantages of gene manipulation, ease of use, high throughput, and low cost. 
5. Approaches to prevent CIA 
Several approaches have been investigated to overcome CIA. These approaches can be 
broadly classified as physical and pharmacological, as described below. 
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5.1 Physical prevention 
5.1.1 Scalp torniques 
Scalp torniques are the application of bands around the head to occlude the superficial 
blood flow to scalp, thus reducing the amount of drugs delivered to the hair follicles. The 
torniques range from 10 mmHg above systolic pressure to 300 mmHg around the scalp. 
These torniques are applied 5-10 minutes prior to or at the time of chemotherapy until up to 
30 minutes after the drug administration (Cline, 1984). Although reports described mild to 
moderate prevention of CIA induced by vincristine, cyclophosphamide, and doxorubicin, 
this technique is no longer recommended due to patient discomfort (Wang et al., 2006).  
5.1.2 Scalp cooling  
Scalp cooling or hypothermia is the application of cold to the scalp using a device (cap) that 
is pre-cooled in a freezer or exchanges coolant with reservoir. A period of cooling lasts from 
5 minutes prior to chemotherapy until an hour or more after the drug administration. Many 
studies have shown that the efficacy of scalp cooling can range from 0-90% (for review, see 
Grevelman and Breed, 2005). A recent study reported that scalp cooling helps reduce major 
CIA in patients receiving doxorubicin (60 mg/m2), docetaxel (80 mg/m2), or combination of 
5-fluorouracil (600 mg/m2), epirubicin (60 mg/m2), and cyclophosphamide (600 mg/m2) for 
6 to 9 cycles (Auvinen et al., 2010). The current hypotheses of the protective effect are: (i) 
cooling reduces blood flow to hair follicles by vasoconstriction, resulting in a decrease in the 
amount of drugs available for uptake; and (ii) cooling decreases cellular metabolism and 
drug uptake. Scalp cooling to 20°C was shown to reduce blood flow to 20% of normal flow; 
however, further decrease in the temperature (<18°C) did not result in further decrease in 
scalp blood flow (Janssen et al., 2007). Recent in vitro studies indicate the significant role of 
temperature on keratinocyte cell viability upon doxorubicin chemotherapy; however, there 
is no difference in cell survival between 10°C and 22°C (Janssen et al., 2008). Based on these 
findings, it appears that there is an optimal temperature for scalp cooling (~20°C), and that 
increasing the cooling will only result in patient discomfort. Other factors affecting the 
effectiveness of this method include drug regimen, application and duration of cooling, and 
the cool conductivity (Betcheler, 2001). 
Scalp cooling is practically ineffective if the chemotherapeutic agent is administered as a 
continuous infusion over a prolonged period. Additionally, scalp cooling increases the risk 
of scalp metastasis, and is therefore contraindicated in patients with hematological 
malignancies and cutaneous T-cell lymphoma (Dean et al., 1979; Apisanthanarax and Duvic, 
2003).  
5.1.3 Heat treatment 
Stress protein response is one of the cellular protective mechanisms against various adverse 
conditions. Enhanced expression of stress proteins such as Hsp90, Hsp70, and Hsp25 has 
been observed in response to certain physical and chemical stresses, which has been linked 
to increased stress tolerance. Previous in vitro studies have shown that heat treatment and 
overexpression of stress response proteins, e.g., Hsp70 and Hsp27, could protect against the 
cytotoxic effects of anticancer drugs such as doxorubicin, cyclophosphamide, etoposide, and 
taxol (Kampinga, 1995; Jaattela et al., 1998; Kwak et al., 1998; Ito et al., 1999; Xia et al., 1999), 
leading to the investigation of the protective effect of stress protein activation on CIA in 
neonatal rats (Jimenez et al., 2008). In this study, heat was locally applied to the skin with a 
copper cylinder through which heated water was circulated. Conducting gel (Vaseline) was 
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applied to the skin to improve heat conductance. Heat treatment at 48-48.5°C for 20 minutes 
increases Hsp70 and subsequently protects against CIA in response to various treatments as 
summarized in Table 3. The protective effect of heat treatment was confirmed in an adult 
mouse model receiving cyclophosphamide. Additionally, localized heat treatment was 
shown not to interfere with the anti-tumor activity of drugs. These findings suggest that 
localized activation of stress proteins in the hair follicles might be an effective strategy 
against CIA without affecting the anti-tumor efficacy. 
 
Chemotherapeutic agents Dosing Protective 
Frequency  
Etoposide 
Cyclophosphamide 
Cyclophosphamide/doxorubicin 
Taxol 
I.P. 2.5 µg/g twice 
I.P. 35.5  µg/g twice 
I.P. 20-30 µg/g once/2.5-4.5 µg/g twice 
S.C. 5 µg/animal, twice 
0.94 (45/48) 
0.97 (29/30) 
1.0 (56/56) 
1.0 (7/7) 
Table 3. Localized, heat-induced protection against CIA in neonatal rats. 
5.2 Pharmacological prevention 
Currently, there are no FDA-approved drug treatments for CIA but several pharmacological 
strategies have been proposed. Many of these strategies have shown promising results in 
animals but their clinical use will require further investigations.  
5.2.1 Tumor targeting delivery 
Differences in the molecular machinery of normal cells and tumor cells as a result of cell 
transformation dominate the tumor targeting delivery arena. Tumor-specific ligands and 
antibodies have been used to provide targeting ability to drug carriers such as liposomes. 
Accordingly, these liposomes can protect patients from the side effects of chemotherapy, 
including hair loss. Examples of the targeting moieties are folate receptor (FR) for ovarian, 
colorectal, and breast cancer; transferrin for pancreatic cancer; anti-HER2 antibody for breast 
cancer; anti-CD19 for malignant B cells; anti-GD2 for neuroblastoma and melonoma; and 
prostate-specific membrane antigen (PMSA) aptamer for prostate cancer and tumor vascular 
endothelium (Huges et al., 2001; Yu et al., 2009). 
5.2.2 Drug-specific antibodies 
MAD11 monoclonal antibody (MAb) is an anti-anthracycline antibody that reacts with 
doxorubicin and other anthracycline chemotherapeutics. Topical administration of 
liposomes containing MAD11 MAb was shown to prevent CIA in doxorubicin-treated 
neonatal rats at the frequency of 31 in 45 rats (Balsari et al., 1994). MAD11 MAb was 
encapsulated into liposomes to facilitate absorption through the stratum corneum and to 
delay systemic distribution of the antibody. Topical MAD11 MAb was found to be nontoxic 
and does not induce systemic activation of cytokines. Thus, MAD11-loaded liposomes 
might be an effective strategy in preventing anthracycline-induced alopecia in cancer 
patients. However, the advantage of this strategy is limited in combination therapy since the 
antibody could not react with the other drugs in combination. 
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5.2.3 Hair growth cycle modifiers 
5.2.3.1 Cyclosporine A 
Cyclosporine A is an immunosuppressive immunophilin ligand used in the treatment of 
autoimmune diseases and in post-organ transplantation to reduce patients’ graft rejection. In T-
lymphocytes, cyclosporine A forms complex with cyclophilin and inhibits calcineurin, leading 
to the inhibition of Go to G1 cell cycle transition and proliferation. The use of cyclosporine A in 
alopecia originates from its common side effect of excessive hair growth called hypertrichosis. 
Cyclosporin A induces anagen and inhibits catagen of the hair cycle, leading to the promotion 
of hair growth under normal and pathologic conditions such as alopecia areata and 
androgenetic alopecia (Paus et al., 1989; Taylor et al., 1993; Lutz et al., 1994).  
The effect of cyclosporine A on CIA has been investigated in neonatal rat and adult mouse 
models. In neonatal rats, topical administration of cyclosporine A prevents CIA induced by 
cyclophosphamide, cytosine arabinoside and etoposide (Hussein et al., 1995). In adult mice 
given cyclophosphamide, topical or systemic administration of cyclosporine A retards CIA, 
prevents the progression of damaged hair into telogen, and thus induces faster hair 
regrowth.  
5.2.3.2 AS101 
AS101, ammonium trichloro (dioxoethylene-o,o') tellurate, is a synthetic  immunomodulator 
that has been shown to protect mice from hemopoietic damage caused by chemotherapeutic 
agents such as cyclophosphamide, 5-fluorouracil, doxorubicin and etoposide. In phase II 
clinical trials, AS101 was shown to protect against CIA in patients with non-small cell lung 
cancer (NSCLC) receiving a combination therapy of carboplatin and etoposide (Sredni et al., 
1996). The results of this study are summarized in Table 4. 
 
Treatments No.  
of patients 
% of patients in alopecia grade 
No Mild Moderate Severe Total 
Carboplatin and etoposide 
+ AS101 
30 
28 
20.4 
37.2 
5.1 
16.2 
28.2 
27.9 
38.5 
13.9 
7.7 
4.6 
Table 4. Prevention of alopecia in AS101-treated NSCLC patients. 
The mechanism of action of AS101 was investigated in neonatal rats receiving cytosine 
arabinoside (Sredni et al., 1996). The study demonstrated that the protective effect of AS101 
was through macrophage-derived factors such as interleukin-1 (IL-1). IL-1 induces the 
secretion of other cytokines such as keratinocyte growth factor (KGF) which stimulate the 
proliferation and differentiation of keratinocytes within the hair follicles.  
5.2.3.3 Minoxidil 
Minoxidil is one of the FDA approved drug for the treatment of androgenetic alopecia. 
Topical minoxidil shortens the telogen phase by inducing the entry of resting hair follicles 
into the anagen phase, thereby stimulating hair growth (Messenger and Rundegren, 2004). 
Minoxidil also prolongs the duration of anagen phase and enlarges hair follicles, probably 
by its proliferative and anti-apoptotic effects on dermal papilla cells (Han et al., 2004). 
Several studies have also investigated the effect of minoxidil on CIA. In neonatal rats, local 
injection of minoxidil protects against CIA induced by cytosine arabinoside but not by 
cyclophosphamide. However, topical minoxidil (2%) does not protect against CIA. In one 
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randomized clinical trial, topical minoxidil (2%) was shown to shorten the duration of CIA 
in breast cancer patients receiving 5-fluorouracil, doxorubicin, and cyclophosphamide 
(Duvic et al., 1996). The results of this study is summarized in Table 5.  
 
Interval 
Mean (days) 
p-value 
Minoxidil Placebo 
Baseline to maximal hair loss 
Baseline to maximal regrowth 
Maximal hair loss to first regrowth (period of baldness) 
Baseline to first moderate or dense hair growth 
61.8 
148.5 
86.7 
131.2 
50.3 
187.2 
136.9 
155.3 
0.15 
0.07 
0.03 
0.40 
Table 5. Minoxidil shortens duration of CIA. 
5.2.4 Cytokines and growth factors 
Hair follicle cells express receptors for multiple cytokines and growth factors that regulate 
hair growth cycle (Trueb, 2002). These regulators include fibroblast growth factors (FGF), 
transforming growth factors (TGF), insulin-like growth factors (IGF), epidermal growth 
factors (EGF), interferon and interleukins (Stenn and Paus, 2001).  Moreover, hair cycle is 
regulated by androgens and parathyroid hormone (PTH) (Sawaya, 2001). 
IL-1 and ImuVert, a biological response modifier derived from S. Marcescens, were reported 
to protect against CIA induced by cytosine arabinoside and doxorubicin in neonatal rats 
(Hussesin, 1993). Both agents can induce the release of multiple cytokines and growth 
factors. It was suggested that the protection of CIA by ImuVert is mediated through IL-1. 
Similarly, EGF and FGF-1 have been shown to protect against CIA induced by cytosine 
arabinoside but not by cyclophosphamide in neonatal rats (Jimenez and Yunis, 1992). In 
contrast, FGF-7 and KGF partially protect against CIA by cytosine arabinoside by retarding 
hair loss (Danilenko et al., 2000). In organ-culture human scalp hair follicles and HaCaT 
keratinocytes, KGF protects against the cytotoxicity of mafosfamide, the cell culture active 
derivative of cyclophosphamide (Braun et al., 2006). The mechanism of action of KGF has 
been proposed to involve specific signaling pathways including PI3K and ERK1/2. 
PTH antagonists reduce cell apoptosis in the hair bulb matrix and delay the onset of CIA in 
adult mice, whereas PTH agonists enhance the apoptosis and accelerate hair regrowth after 
CIA. However, neither PTH agonists nor antagonists prevent CIA (Peters et al., 2001). 
5.2.5 Antioxidants 
Broad spectrum antioxidant N-acetyl cysteine (NAC), an analog and precursor of 
glutathione, when administered topically or parenterally, protects against CIA induced by 
cyclophosphamide in neonatal rats. In contrast, NAC could not protect adult mice from CIA 
induced by doxorubicin (Wang et al., 2006).  
-Tocopherol or vitamin E is an important lipid-soluble antioxidant. Several studies have 
reported the protective effect of high-dose vitamin E in patients receiving doxorubicin; 
however, conflicting results have also been reported. For example, A clinical study reported 
that 69% of the patients did not experience CIA when co-treated with vitamin E, while 
others reported no protective effect of vitamin E (Batchelor, 2001).  
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5.2.6 Cell cycle or proliferation modifiers 
Rapid proliferation of keratinocytes during the anagen phase of hair follicle is one the main 
predisposing factors of CIA. Thus, one approach to protect against CIA is to arrest the cell 
cycle and inhibit cell proliferation.  
5.2.6.1 Calcitriol 
Multiple effects of calcitriol (1,25-dihydroxyvitamin D3) on keratinocytes, i.e., inhibition 
of DNA synthesis, Go/G1 cell cycle arrest, and induction of cell differentiation, have been 
reported (Kobayashi et al., 1998; Wang et al., 2006). Thus, it is likely that calcitriol induces 
changes in keratinocyte proliferation and/or terminal differentiation, subsequently 
altering cellular susceptibility to apoptosis. In neonatal rats, topical administration of 
calcitriol reduces CIA induced by cyclophosphamide, etoposide, and a combination 
treatment of cyclophosphamide and doxorubicin (Jimenez and Yunis., 1992). In adult mice 
receiving cyclophosphamide, topical calcitriol however fails to prevent or retard CIA, but 
somehow reduces massive apoptosis of hair matrix keratinocytes, a key feature of CIA, 
and enhances the regrowth of normal hair shaft. (Paus et al., 1996;  Schilli et al., 1998). In 
humans, calcitriol has a protective effect against CIA induced by paclitaxel (Jimenez and 
Yunis, 1996), but not by a combination of 5-fluorouracil, doxorubicin and 
cyclophosphamide (Hidalgo et al., 1999)   
5.2.6.2 CDK2 inhibitor 
Cyclin-dependent kinase 2 (CDK2) is a member of the serine/threonine protein kinase 
family that plays a key role from late G1 to late G2 of the cell cycle. Potent small inhibitors of 
CDK2 have been synthesized and tested for their effect on CIA. One of these synthetic 
inhibitors was shown to inhibit the progression from late G1 into S phase in human diploid 
fibroblasts and also inhibit apoptosis induced by etoposide, 5-fluorouracil, taxol, cisplatin 
and doxorubicin. In neonatal rats, topical application of the inhibitor reduces hair loss at the 
site of application in 50% of the rats having etoposide-induced CIA and in 33% of the rats 
with CIA induced by cyclophosphamide and doxorubicin (Davis et al., 2001). Histological 
examinations of the skin from etoposide-treated rats show that the inhibitor increases the 
number of viable hair follicles and dermal papilla, reduces the level of inflammation and 
amount of damage to epithelium, reduces the thickening of epidermis and decreases the 
number of apoptotic cells in the hair follicle matrix. However, in subsequent studies the 
authors reported that they were unable to reproduce the results in the neonatal rat model 
(Davis et al., 2002), thus the use of this inhibitor in CIA becomes questionable, although the 
idea of using CDK2 inhibitors is still ongoing.  
5.2.7 Inhibitor of apoptosis 
5.2.7.1 Caspase3 inhibitor 
Various chemotherapeutic agents induce apoptosis of hair follicle cells and cause CIA, 
although the underlying mechanisms are unclear. Caspase-3 is a key executor of apoptosis 
and its activation is normally used as an indicator of caspase-dependent apoptosis (Porter 
and Janicke, 1999). M50054, 2,2’-methylenebis, is an inhibitor of caspase-3 activation that 
was shown to inhibit etoposide-induced apoptosis in human monocytes. In neonatal rats, 
topical administration of M50054 reduces CIA induced by etoposide (Tsuda et al., 2001).  
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5.2.7.2 Anti-death FNK protein 
FNK protein constructed from rat Bcl-xL by site-directed mutagenesis 
(Y22F/Q26N/R165K) localizes to mitochondria and functions to maintain mitochondrial 
membrane potential (Aosh et al., 2000). Mitochondrial membrane potential regulates the 
release of cytochrome C, which once binds to caspase-activating proteins such as Apaf-1 
initiates the intrinsic caspase cascade and apoptosis (Li et al., 1997). Recently, FNK protein 
has been fused to protein transduction domain (PTD) to improve its cellular entry. 
Subcutaneous injection of PTD-FNK protects against CIA induced by etoposide in the 
neonatal rat model. The fusion protein helps retain hair follicle structures, prevent hair 
follicle regression and maintain the anagen duration upon etoposide treatment 
(Nakashima-Kamimura et al., 2008). Indeed, its protective effect on CIA suggests that it 
could penetrate the epidermis and reach the dermal hair follicles. Localized 
administration of FNK fusion protein has been suggested as a potential protein therapy 
for CIA without affecting the chemotherapy efficacy. 
6. Molecular mechanisms of CIA 
Molecular mechanisms of CIA are not well understood, in part due to the lack of 
appropriate experimental models that mimic human CIA. Much of our understanding on 
CIA is based on animal and cell culture models, some of which are described below.   
6.1 DNA damage 
Most chemotherapeutic agents including cyclophosphamide, doxorubicin and cisplatin 
induce DNA damage and kill both normal and cancer cells by apoptosis (Muller et al., 1998). 
p53 is a transcription factor and tumor suppressor protein that plays a critical role in cell 
cycle progression and apoptosis. Activation of p53 in response to DNA damage is associated 
with the degradation of Mdm2/p53 complex, leading to increased availability of p53 to bind 
DNA and consequently transcriptional activation of p53 target genes. Many p53 target 
genes, including Fas, Bax, Bcl-2, insulin-growth factor receptor type I (IGFR1), and insulin-
like growth factor binding protein 3 (IGF-BP3), are expressed in the hair follicles (Lindner et 
al., 1997). In the adult mouse model for CIA, p53 was shown to be essential in the hair 
follicle response to DNA damage induced by cyclophosphamide. Specifically, hair loss was 
not observed and hair follicle cells remained active in p53-deficient mice, as shown by a 
large volume of hair bulb and dermal papilla, and active keratinocyte proliferation in the 
hair matrix (Botchkarev et al., 2000).  
6.2 Apoptosis 
Chemotherapy-induced apoptosis of hair follicle cells is one of the major findings from CIA 
animal studies. Although the mechanism of apoptosis is not well understood, p53 and Fas 
signaling pathways are believed to play a key role. 
In adult mice, cyclophosphamide-treated hair follicles show a strong up-regulation of p53 in 
the hair matrix, particularly in TUNEL-positive apoptotic keratinocytes (Botchkarev et al., 
2000). By contrast, in p53-deficient mice, apoptosis in the matrix keratinocytes was not 
detected after cyclophosphamide treatment, indicating the involvement of p53 in the 
apoptotic process. The precise mechanism of p53-dependent apoptosis in the hair follicles 
remains unclear, but likely involves several p53 target genes. Cyclophosphamide-treated 
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p53-deficient mice show strongly down-regulated Fas in the hair follicle keratinocytes and 
highly up-regulated Bcl-2 in the dermal papilla as compared to wild-type mice. The role of 
Fas in the control of cyclophosphamide-induced apoptosis in keratinocytes was also 
investigated using Fas-deficient mice (Sharov et al., 2004). These mice show significantly 
reduced CIA and a parallel decrease in apoptotic keratinocytes and FADD and caspase-8 
expression. Similarly, anti-Fas ligand neutralizing antibody inhibits cyclophosphamide-
induced keratinocyte apoptosis. These studies indicate that Fas signaling is an important 
pathway in mediating the apoptosis induced by cyclophosphamide and suggest the cross-
talk between p53 and Fas death signaling. However, the eventual hair loss observed in Fas-
deficient mice points to the lower resistance of hair follicles to cyclophosphamide as 
compared to p53-deficient mice. Thus, it is likely that Fas signaling represents only a 
component of the p53-dependent apoptosis machinery in the hair follicles and that other p53 
targets are also involved. Cyclophosphamide treatment also alters the expression of 
melanogenic proteins and causes apoptosis of hair follicle melanocytes (Sharov et al., 2003). 
In contrast to matrix keratinocytes, the melanocytes undergo apoptosis primarily through 
Fas signaling but not p53 signaling. 
6.3 Reactive oxygen species 
The observation that antioxidants such as NAC protect against CIA in animals suggest the 
involvement of reactive oxygen species (ROS) in CIA. Various chemotherapeutic agents 
induce oxidative stress through multiple mechanisms, i.e., activation of NADPH oxidase 
system and mitochondrial respiration chain. Agents that induce a high level of ROS include 
anthracyclines (e.g., doxorubicin, epirubicin, and daunorubicin), alkylating agents (e.g., 
cyclophosphamide), platinum coordination complexes (e.g., cisplatin, carboplatin, and 
oxaliplatin), and epipodophyllotoxins (e.g., etoposide) (Conklin, 2004). Interestingly, 
anthracyclines, alkylating agents, platinum complexes, and epipodophyllotoxins also induce 
CIA more frequently and more severely than most other agents, suggesting a relationship 
between ROS generation and CIA. The exact mechanism of how ROS induces or promotes 
CIA is unclear, but likely involves apoptosis regulation since apoptosis of hair follicles is a 
hallmark of CIA and since ROS generation is generally required for the induction of 
apoptosis by chemotherapeutic agents (Simon et al., 2000).  
7. Perspectives 
CIA is a major side effect that compromises patient quality of life, particularly for females 
and children. Overcoming CIA remains a major challenge in the management of cancer 
patients. Significant progresses in the pathobiology and molecular mechanisms of CIA have 
been made during the past decade, and several physical and pharmacological approaches to 
treat CIA have been attempted. However, effective treatment strategies have yet to be 
developed. A key to this success is a better understanding of the human CIA mechanisms 
which requires the development of more predictive experimental models. Animal models 
have been useful but have limitations and may not be predictive of human CIA. The newly 
developed organ culture system using human hair follicles is promising and could lead to 
the development of more effective treatment strategies for CIA. The recent success in 
combination chemotherapy also provides mechanistic insights to combating CIA through 
the use of different combination strategies.  
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Even if CIA cannot be completely prevented, it can be managed. Healthcare providers and 
patient family could help patients prepare for the sudden loss of hair, thus minimizing the 
negative impact on patients. Patients should receive the information regarding self-care 
strategies to take control and cope with CIA. Patients with long hair should be encouraged 
to try short hair style to make a better transition to total CIA. Patients are also advised to 
avoid physical and chemical trauma to the hair (e.g. bleaching, coloring and perming) and 
to shave their hair once the hair loss becomes prominent. Appropriate head covering may be 
used, depending on individual preference (Bachelor, 2001; Trueb, 2010).  
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